Bristol, Pharmasset To Study Oral HCV Regimen Together
This article was originally published in The Pink Sheet Daily
Executive Summary
Partnership to study Bristol's NS5A inhibitor with Pharmasset's polymerase inhibitor is the first cross-company collaboration to study two oral agents in hepatitis C.
You may also be interested in...
Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset
The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.
Pharmasset: A Breakout Year But Big Catalysts Lie Ahead
Although only half over, 2011 already has been pivotal for hepatitis C drug development, with the launch of two paradigm-shifting protease inhibitors, Johnson & Johnson/Vertex Pharmaceuticals Inc.'s Incivek (telaprevir) and Merck & Co.'s Victrelis (boceprevir). Both hit the market in May, even as attention is now shifting to the next big advance in HCV. Based on its work on next-gen HCV treatment, Pharmasset, Inc. has captivated the investment community.
Pharmasset: A Breakout Year But Big Catalysts Lie Ahead
Although only half over, 2011 already has been pivotal for hepatitis C drug development, with the launch of two paradigm-shifting protease inhibitors, Johnson & Johnson/Vertex Pharmaceuticals Inc.'s Incivek (telaprevir) and Merck & Co.'s Victrelis (boceprevir). Both hit the market in May, even as attention is now shifting to the next big advance in HCV. Based on its work on next-gen HCV treatment, Pharmasset, Inc. has captivated the investment community.